The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice

Nature Medicine

Volumn 7, Issue 9, 2001, Pages 1052-1056

  Hong, Seokmann ^a   Wilson, Michael T ^a   Serizawa, Isao ^b   Wu, Lan ^a   Singh, Nagendra ^a   Naidenko, Olga V ^c   Miura, Toru ^b   Haba, Tomoku ^b   Scherer, David C ^a   Wei, Jie ^a   Kronenberg, Mitchell ^c   Koezuka, Yasuhiko ^b   Van Kaer, Luc ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KIRIN BREWERY CO LTD   (Japan)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; AUTOANTIGEN; CERAMIDE DERIVATIVE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; OBESITY; PANCREAS ISLET CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

ANIMALS; ANTIGENS, CD1; AUTOANTIGENS; CONCANAVALIN A; DIABETES MELLITUS, TYPE 1; FEMALE; GALACTOSYLCERAMIDES; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; LIGANDS; MICE; MICE, INBRED NOD; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; SPLEEN; TH2 CELLS;

EID: 0034786013     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0901-1052     Document Type: Article

References (25)

1. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD
2. Tolerance to islet autoantigens in type 1 diabetes
3. NKT cells: Facts, functions and fallacies
4. α14 NKT cells by glycosylceramides
5. Activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
6. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
7. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
8. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells
9. +-like thymocytes in the NOD mouse
10. − T cell deficiency and IDDM in NOD/Lt mice
11. A defect in interleukin 12-induced activation and interferon γ secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus
12. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
13. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
14. Redirecting Th1 and Th2 responses in autoimmune disease
15. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4
16. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse
17. − immunoregulatory T cells that control autoimmune diabetes
18. − (NKT) thymocytes prevent insulin-dependent diabetes mellitus in non-obese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10
19. NK T cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen
20. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide
21. Structure-function relationship of α-galactosylceramides against B16-bearing mice
22. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site
23. NKT cell-mediated repression of tumor surveillance by IL-13 and the IL-4R-STAT6 pathway
24. Immune suppression and skin cancer development: Regulation by NKT cells
25. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes